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Abstract
Deep vein thrombosis (DVT) and subsequent pulmonary
embolism (PE) are uncommon postoperative complications
of operative procedures for treating injuries of the foot
and ankle. Because the disorder of hemophilia A prevents
blood clotting and increases bleeding, patients with this
condition have been even less likely to develop DVT and
PE. We present a 36-year-old man with hemophilia A
in whom operative ankle fusion for treating hemophilic
arthropathy of the left ankle led to DVT and PE. After
decreasing dosage of antihemophilic medication and
administering enoxaparin, the symptoms improved and the
patient was discharged from the hospital on postoperative
day 5. At 3-month follow-up with continued dosage, no
complications were reported. Surgeons should be aware of
possible DVT and PE in patients with hemophilia A and
consider multidisciplinary efforts to successfully treat the
resultant symptoms.

Introduction
Deep vein thrombosis (DVT) is an uncommon complication
after operative treatment of the foot and ankle, with a
documented prevalence between 0.03% and 0.27% in
patients after undergoing elective hindfoot fusion.1,2
Currently, about 43% of physicians have recommended
routine use of chemical thromboprophylaxis in operatively
treating the foot and ankle of patients without history of
DVT.3 However, the American Academy of Orthopaedic
Surgeons has no specific recommendations for DVT
prophylaxis after foot and ankle procedures.4
In particular, DVT and subsequent pulmonary
embolism (PE) rarely occur in patients with hemophilia
A, an X-linked disorder of factor VIII. Patients with this
condition have difficulties with forming blood clots and are
thus at risk for developing spontaneous bleeding into joints,
which can severely damage cartilage and result in arthritis.
Owing to infrequent blood clotting, it is counterintuitive
that patients with hemophilia A could develop blood clots
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associated with DVT and PE. We performed left ankle
fusion to treat hemophilic arthropathy in a 36-year-old
man with hemophilia A, which resulted in development of
DVT and PE.

Case Report
A 36-year-old man with a medical history of hemophilia A
presented to our institution with pain and history of bleeding
in the left ankle. Previously, the patient had undergone right
ankle fusion for treating severe degenerative hemophilic
arthropathy, resulting in almost complete resolution of
symptoms. He returned to the clinic several years later, with
progressive worsening of pain in the left ankle. Radiographs
obtained at evaluation showed arthritic changes suggestive
of hemophilic arthropathy about the left ankle joint. Loss
of joint space and signs of osteophytes were noted (Figure
1). The patient had considerable pain despite using previous
nonoperative methods for treatment.
Preoperatively, the patient underwent a routine evaluation
led by hematologists and oncologists. A perioperative plan
for dosage of antihemophilic factor VIII (50 units/kg) was
established, which included one preoperative dose in the
morning and two doses per day after the procedure, with
close follow-up monitoring of factor VIII levels.
A total of 5090 units of antihemophilic factor VIII was
administered to the patient. He underwent ankle fusion
without observed complications (Figure 2) and was after
admitted to the hospital for standard care. On postoperative
day 1, he began receiving doses of antihemophilic factor
VIII twice per day. Initial outcomes were promising, with
limited pain and no symptoms of increased bleeding in
the left ankle. On postoperative day 3, labored breathing
was noted and thereby oxygen levels were increased. The
patient underwent a computed tomography angiogram of
the pulmonary arteries, during which PE was diagnosed in
the right main pulmonary artery with extension into the
right-middle and lower-lobe branches. Hematologists and
oncologists were consulted. Subsequently, the dosage of
antihemophilic factor VIII was decreased to once a day and

the patient was administered low-molecular weight heparin
(ie, enoxaparin) at doses of 1.5 mg/kg for therapeutic
purposes. Clinical signs of improvement were observed
during the next 2 days, without further progression of
symptoms. He was discharged on postoperative day 5.
Based on factor VIII levels at discharge, the dosage of
antihemophilic factor VIII was reduced by 50% and the
patient remained on enoxaparin for therapeutic treatment
of PE. He was followed at regular intervals by orthopaedic,
hematologic, and oncologic physicians. At 3 months
postoperatively, symptoms of pain and PE had resolved,
without any additional complications. Use of antihemophilic
factor VIII and enoxaparin were discontinued.

Figure 1. Preoperative radiographs of the left ankle joint, showing
arthritic changes suggestive of hemophilic arthropathy, with loss
of joint space and presence of osteophytes.

Figure 2. Postoperative radiographs of the left ankle joint obtained
immediately after ankle fusion, showing initial improvement of
joint space.

Discussion
Hemophilia A is characterized by a deficiency in coagulation
of factor VIII, which typically results in hemorrhagic
complications after operative treatment. However, the
results of the current case suggest that the disorder does
not completely prevent development of DVT and PE.
Only 13 cases have found non–catheter-related thrombus
in patients with hemophilia A, in which none involved
operative treatment of the foot and ankle.5 None of these
cases involve surgery about the foot and ankle.
Patients with hemophilia A undergoing replacement
therapies of factor VIII (eg, factor VIII inhibitor bypassing
activity and recombinant activated factor VII) may have
a closer risk factor for DVT and PE to that of the patients
without the disorder. In other words, the most prevalent risk
factor in patients with hemophilia A could be the presence of
replacement therapies. However, the incidence of DVT and
PE in patients with hemophilia A undergoing replacement
therapies has been low, in which no definitive protocol
exists for treating perioperative thromboprophylaxis in
major hemophilia treatment centers. Previous case studies
have noted that some patients may have a concomitant
inheritable prothrombotic condition such as protein c
deficiency or factor V Leiden.5 In treating patients with
family history of DVT and PE, Dargaud et al6 suggested
performing a complete thrombophilic evaluation of
inheritable risk factors to identify potential indications for
thromboprophylaxis.
No standard protocol exists for optimizing the type or
dosage of anticoagulation medication using appropriate
techniques for replacing clotting factors (ie, factor VIII).
Additionally, consensus has not been established regarding
the duration of such treatment. Reported cases suggest that
low-molecular weight heparin or unfractionated heparin
should be used initially for replacement of factors VIII
and IX. To simultaneously achieve peak activity levels of
factors VIII and IX, therapeutic dosage of heparin has been
recommended in precise coordination with replacement
medication. The authors recommended a treatment
duration of 3 and 6 months for temporary risk factors
(eg, operative treatment) and permanent risk factors (eg,
inheritable traits), respectively.6
The occurrence of DVT and PE in patients with hemophilia
A is rare. A detailed personal and family history of clotting
should be relayed to hematologists to allow for appropriate
workup. The plan for treatment with thromboprophylaxis,
if indicated, can be completed before operative treatment.
Orthopaedic surgeons should be aware of these possible
complications in patients with hemophilia A, in which
successful treatment can involve multidisciplinary efforts
with hematologists and oncologists.
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